PRRT is primarily used to treat neuroendocrine tumors (NETs), which can occur in various parts of the body including the pancreas, intestines, and lungs. These tumors often express high levels of somatostatin receptors, making them ideal candidates for PRRT. The therapy has also shown promise in treating other types of cancers that have similar receptor profiles, though its use outside of NETs is still under investigation.
